Cymabay therapeutics, inc. (CBAY)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Collaboration revenue

-

-

-

-

-

-

-

-

-

10,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Operating expenses:
Research and development

74,758

83,837

79,297

73,957

67,235

58,124

48,396

34,727

24,374

18,938

16,117

15,467

15,554

15,941

16,144

17,138

17,267

17,026

18,252

17,572

17,395

15,823

11,909

8,764

5,650

4,525

5,444

0

0

0

General and administrative

17,922

19,238

18,864

17,626

16,671

14,381

13,117

12,051

12,059

12,387

12,332

12,252

10,885

9,645

8,602

8,673

8,743

8,871

9,407

8,893

8,274

8,185

7,944

6,940

6,446

4,871

3,705

0

0

0

Restructuring charges

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

97,826

108,150

98,161

91,583

83,906

72,505

61,513

46,778

36,433

31,325

28,449

27,719

26,439

25,586

24,746

25,811

26,010

25,897

27,659

26,465

25,669

24,008

19,853

15,704

12,096

9,396

9,149

0

0

0

Loss from operations

-97,826

-108,150

-98,161

-91,583

-83,906

-72,505

-56,306

-41,571

-31,226

-21,325

-23,656

-22,926

-21,646

-25,586

-24,746

-25,811

-26,010

-25,897

-27,659

-26,465

-25,669

-24,008

-19,853

-15,704

-12,096

-9,396

-6,236

0

0

0

Other income (expense):
Interest income

5,005

5,342

5,317

5,005

4,456

3,988

3,206

2,309

1,292

621

327

156

160

176

207

208

186

160

125

98

89

74

57

37

21

10

4

0

0

0

Interest expense

-

-

-

-

-

336

570

828

983

1,080

1,174

1,257

1,310

1,337

1,338

1,262

1,091

913

775

701

725

755

746

774

794

822

860

0

0

0

Loss on extinguishment of debt

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

-

-

-

-

-

-3,288

-4,065

-7,316

-8,294

-5,773

-4,963

-3,084

-2,378

76

179

1,181

6,866

11,121

6,037

4,700

2,122

-7,228

-2,567

-2,015

-4,638

135

422

0

0

0

Total other income (expense)

5,005

5,342

5,317

6,458

5,288

-43

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-92,825

-102,800

-92,844

-85,125

-78,618

-72,548

-58,142

-47,813

-39,211

-27,557

-29,466

-27,111

-25,174

-26,671

-25,698

-25,684

-20,049

-15,529

-22,272

-22,368

-24,183

-31,917

-23,110

-18,456

-17,507

-10,073

-6,669

0

0

0

Net (loss) income attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

243,994

28,076

0

0

0

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Net loss

-92,825

-102,800

-92,844

-85,125

-78,618

-72,548

-58,142

-47,813

-39,211

-27,557

-29,466

-27,111

-25,174

-26,671

-25,698

-25,684

-20,049

-15,529

-22,272

-22,368

-24,183

-31,917

-23,110

-18,456

-17,507

-10,073

-6,669

0

0

0

Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities

-175

138

208

295

177

-14

-18

-66

-130

-43

-11

4

-1

20

6

8

6

-7

6

-14

-10

-16

0

0

0

-

-

-

-

0

Total other comprehensive (loss) income

-175

138

208

295

177

-14

-18

-66

-130

-43

-11

4

-1

20

6

8

6

-7

6

-14

-10

-16

0

0

0

-

-

-

-

0

Comprehensive loss

-92,996

-102,670

-92,636

-84,830

-78,441

-72,562

-58,160

-47,879

-39,341

-27,600

-29,477

-27,107

-25,175

-26,651

-25,692

-25,676

-20,043

-15,536

-22,266

-22,382

-24,193

-31,933

-20,015

-15,346

-14,395

-10,071

-9,780

0

0

0

Basic net loss per common share

-0.19

-0.43

-0.38

-0.35

-0.37

-0.32

-0.31

-0.30

-0.32

-0.07

-0.21

-0.31

-0.20

-0.30

-0.25

-0.30

-0.29

-0.31

-0.27

-0.09

-0.15

-0.87

-0.44

-0.32

-1.02

-

422.95

-917.59

-

-637.05

Diluted net loss per common share

-0.19

-0.43

-0.38

-0.35

-0.37

-0.30

-0.34

-0.30

-0.32

-0.07

-0.21

-0.31

-0.20

-0.30

-0.25

-0.30

-0.29

-0.03

-0.27

-0.09

-0.44

-0.63

-0.44

-0.56

-1.02

-

-1.79

-917.59

-

-637.50

Weighted average common shares outstanding used to calculate basic net loss per common share

68,882

68,842

68,701

68,697

61,890

59,525

59,121

58,833

53,752

44,217

40,035

28,752

26,609

23,447

23,447

23,447

23,447

23,569

21,674

15,258

15,099

14,789

13,468

10,064

9,873

-

101

5

-

5

Weighted average common shares outstanding used to calculate diluted net loss per common share

68,882

68,842

68,701

68,697

61,890

59,306

59,387

58,905

53,752

44,217

40,035

28,752

26,609

23,447

23,447

23,447

23,447

22,992

21,674

15,258

15,743

14,366

13,468

10,487

9,873

-

731

5

-

5

Basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-985.06

-

Weighted average common shares outstanding used to calculate basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

-